GlassScriptPhysician profile
Veronica Dawson Sharp
NPI 1174075329
$8,960.32
in general payments reported to CMS, 2019-2025
45 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,894 · 2022: $1,729 · 2023: $2,281 · 2024: $1,961 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,063 · Long Term Medical Supply Or Device Loan: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.74 |
| Long Term Medical Supply Or Device Loan | $274.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,508.44 | 2021-2025 | Freestyle Libre, Freestyle Copilot |
| Corcept Therapeutics | $687.38 | 2021-2024 | Korlym |
| Radius Health, INC. | $685.03 | 2021-2025 | |
| Amgen INC. | $673.39 | 2021-2025 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $656.71 | 2021-2025 | |
| Lilly USA, LLC | $597.57 | 2022-2025 | Mounjaro, Jardiance, Baqsimi |
| Novo Nordisk INC | $544.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $483.42 | 2021-2024 | Strensiq, Ultomiris |
| Xeris Pharmaceuticals, INC. | $409.78 | 2022-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Dexcom, INC. | $273.10 | 2022-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $243.63 | 2022-2023 | Glassia |
| Ibsa Pharma INC. | $239.09 | 2021-2023 | Tirosint, Licart |
| Horizon Therapeutics Plc | $219.52 | 2021-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $163.34 | 2021-2025 | |
| Pfizer INC. | $143.64 | 2021-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $120.95 | 2023-2025 | Yorvipath |
| Actelion Pharmaceuticals US, INC. | $116.77 | 2022-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $106.64 | 2021-2023 | Orenitram, Tyvaso |
| Electromed, INC. | $103.54 | 2022-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $103.35 | 2021-2024 | |
| Baxter Healthcare | $87.38 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $80.12 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Amneal Pharmaceuticals LLC | $76.76 | 2021-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $68.01 | 2024-2025 | |
| Insulet Corporation | $54.06 | 2022 | |
| Kyowa Kirin, INC. | $50.03 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.36 | 2022-2023 | Jardiance |
| Grifols USA, LLC | $41.67 | 2021-2025 | Prolastin-C Liquid |
| Medtronic, INC. | $40.27 | 2022-2025 | Inceptiv |
| Astellas Pharma US INC | $35.24 | 2023 | Veozah |
| Mylan Specialty L.P. | $29.36 | 2023 | Yupelri |
| Vanda Pharmaceuticals INC. | $27.87 | 2022 | |
| Amryt Pharma Holdings LTD | $24.51 | 2023 | Mycapssa |
| Aurinia Pharma U.S., INC. | $23.51 | 2025 | Lupkynis |
| Glaxosmithkline, LLC. | $22.80 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $22.10 | 2024 | Evkeeza |
| Chiesi USA, INC. | $21.23 | 2024 | Mycapssa |
| Viatris Specialty LLC | $20.40 | 2025 | Yupelri |
| Fresenius Kabi USA, LLC | $19.80 | 2024 | Idacio |
| Sandoz INC. | $17.52 | 2022 | |
| Grt US Holding, INC. | $14.92 | 2021 | |
| Invivyd INC | $14.79 | 2025 | Pemgarda |
| Renalytix Ai, INC. | $14.30 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Tandem Diabetes Care, INC. | $13.84 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $13.74 | 2024 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.